Want to see KR:234080 full AI Analyst Report?
JW LIFESCIENCE CORPORATION (234080) AI Stock Analysis
JW LIFESCIENCE CORPORATION
(Korea Exchange:234080)
The score is driven primarily by solid underlying financial health (steady growth, reasonable profitability, and conservative leverage) and strong valuation support (low P/E and high dividend yield). These positives are partially offset by weak technical conditions, with the stock in a clear downtrend despite oversold indicators.
JW LIFESCIENCE CORPORATION (234080) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- KRW 162.74B
- Dividend Yield
- 5.23%
- Average Volume (3M)
- 16.93K
- Price to Earnings (P/E)
- 6.3
- Beta (1Y)
- 0.07
- Revenue Growth
- 1.00%
- EPS Growth
- -47.42%
- Country
- KR
- Employees
- 319
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Pharmaceuticals
JW LIFESCIENCE CORPORATION Business Overview & Revenue Model
Company Description
JW Life Science Corp. manufactures intravenous fluids. Its products include basic IV, nutrition, special fluids, irrigation agents and dialysis solutions. The company was founded on May 10, 1994 and is headquartered in Dangjin-si, South Korea.
JW LIFESCIENCE CORPORATION Financial Statement Overview
Summary
Financial statements indicate solid fundamentals: steady revenue expansion and decent recent profitability, supported by a strengthening, low-leverage balance sheet. Offsets include noticeable margin/earnings normalization versus 2024 and uneven cash conversion with year-to-year volatility.
Income Statement
74PositiveBalance Sheet
81Very PositiveCash Flow
72Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 253.71B | 257.83B | 222.48B | 206.86B | 188.93B | 169.82B |
| Gross Profit | 69.63B | 69.77B | 57.51B | 52.35B | 48.12B | 49.16B |
| EBITDA | 51.81B | 51.41B | 76.82B | 50.83B | 43.75B | 37.59B |
| Net Income | 26.02B | 28.61B | 43.99B | 28.14B | 14.96B | 12.91B |
Balance Sheet | ||||||
| Total Assets | 305.78B | 318.21B | 325.32B | 255.84B | 252.94B | 219.47B |
| Cash, Cash Equivalents and Short-Term Investments | 9.00B | 10.49B | 9.62B | 28.35B | 28.87B | 5.08B |
| Total Debt | 32.37B | 50.57B | 69.24B | 46.31B | 67.20B | 46.49B |
| Total Liabilities | 79.02B | 97.63B | 124.88B | 96.44B | 112.61B | 87.97B |
| Stockholders Equity | 226.76B | 220.58B | 200.44B | 159.39B | 140.33B | 131.49B |
Cash Flow | ||||||
| Free Cash Flow | 35.51B | 27.98B | 40.38B | 29.31B | 5.84B | 10.77B |
| Operating Cash Flow | 47.97B | 40.54B | 50.69B | 37.57B | 14.13B | 30.17B |
| Investing Cash Flow | -13.41B | -13.37B | -68.03B | 8.04B | -28.25B | -22.81B |
| Financing Cash Flow | -34.19B | -26.30B | 1.78B | -29.31B | 13.12B | -5.03B |
JW LIFESCIENCE CORPORATION Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:234080, the sentiment is Negative. The current price of 10510.00 is below the 20-day moving average (MA) of 10678.50, below the 50-day MA of 10943.80, and below the 200-day MA of 11754.50, indicating a bearish trend. The MACD of -135.96 indicates Negative momentum. The RSI at 38.33 is Neutral, neither overbought nor oversold. The STOCH value of 45.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:234080.
JW LIFESCIENCE CORPORATION Peers Comparison
Overall Rating
- KR:23408069Neutral
KR:00385068Neutral
KR:18575057Neutral
KR:00628054Neutral
KR:00322050Neutral
KR:00239044Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| KR:234080 | 69Neutral | KRW 162.74B | 6.25 | ― | 5.23% | 1.00% | -47.42% |
| KR:003850 | 68Neutral | KRW 702.03B | 9.47 | ― | 1.93% | 6.39% | 29.21% |
| KR:185750 | 57Neutral | KRW 831.41B | 10.46 | ― | 0.79% | 7.15% | 29.88% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| KR:006280 | 54Neutral | KRW 1.49T | -29.78 | ― | 1.15% | 9.73% | -167.75% |
| KR:003220 | 50Neutral | KRW 189.25B | 70.81 | ― | 2.88% | 1.83% | -67.89% |
| KR:002390 | 44Neutral | KRW 113.00B | -10.81 | ― | 2.44% | 7.15% | 59.41% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KR:234080 | JW LIFESCIENCE CORPORATION | 10510.00 | -2697.57 | -20.42% | |
| KR:002390 | Handok, Inc. | 8210.00 | -2848.67 | -25.76% | |
| KR:003220 | Daewon Pharmaceutical Co., Ltd | 8680.00 | -4043.59 | -31.78% | |
| KR:003850 | Boryung Corporation | 8310.00 | -461.66 | -5.26% | |
| KR:006280 | GC Biopharma Corp. | 130200.00 | 798.34 | 0.62% | |
| KR:185750 | Chong Kun Dang Pharmaceutical Corp. | 63100.00 | -19812.28 | -23.90% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026